Shares of GlobeImmune, Inc. (OTCMKTS:GBIM – Get Free Report) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.00 and traded as high as $0.00. GlobeImmune shares last traded at $0.00, with a volume of 0 shares changing hands.
GlobeImmune Stock Down 100.0 %
GlobeImmune Company Profile
GlobeImmune, Inc, a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy.
See Also
- Five stocks we like better than GlobeImmune
- 5 discounted opportunities for dividend growth investors
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- What is Put Option Volume?
- 5 Best Gold ETFs for March to Curb Recession Fears
- Breakout Stocks: What They Are and How to Identify Them
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for GlobeImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlobeImmune and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg?v=20240830130102&h=45&w=95&zc=2){kind=logo}
